Anti-IDH1 mAb

価格（税別）

¥37,400

在庫

10以上

（2025/01/24 17:00時点）

包装

100 µL (1 mg/mL)

使用文献

データシート

SDS

Anti-IDH1 (Human) mAb (Clone: RcMab-1) reacts with wild type as well as mutated forms of IDH1 proteins such as R132H, R132S, R132L and R132G.

データ	Western Blotting
クローナリティー	Monoclonal	クローン	RcMab-1
アイソタイプ（免疫動物）	Rat IgG2aκ
使用法	WB 0.5-1 μg/mL IC* reported. （PMID: 23750482） IH* reported. （PMID: 26006098）
交差性 [Gene ID]	Human[3417], Hamster*(PMID: 23485467)
性状	1 mg/mL in PBS/50% glycerol, pH 7.2
保存温度	-20°C	標識	Unlabeled	メーカー	MBL
別称	isocitrate dehydrogenase 1 (NADP+), soluble
背景	Isocitrate dehydrogenase 1 (IDH1) mutations, which have been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as in secondary glioblastomas, might be the initiating event in these glioma subtypes. In contrast, primary glioblastomas, as well as other systemic cancers, rarely contain IDH1 mutations. The IDH1 mutations are remarkably specific to a single codon in the conserved and functionally important Arginine 132 residue (R132) in IDH1. Mutations in the analogous IDH2-R172 codon also occur at a lower rate in these cancers. IDH1/2 mutations were observed subsequently in 22% of acute myeloid leukemias. IDH1 mutations were found to result in the ability of the enzyme to catalyze the reduced NADP-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2-HG). Reduction of α-ketoglutarate by 2-HG or mutant IDH1 results in a lower level of prolyl hydroxylases and promotes the accumulation of hypoxia-inducible factor (HIF) 1α. HIF-1α levels were greater in human gliomas harboring an IDH1 mutation than in tumors without the mutation. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
関連製品	D300-3 Anti-IDH1-R132S (Human) mAb D299-3 Anti-IDH1-R132H (Human) mAb D331-3 Anti-IDH1-R132G (Human) mAb D338-3 Anti-IDH2-R172W (Human) mAb D337-3 Anti-IDH2-R172M (Human) mAb D309-3 Anti-IDH1 mAb D330-3 Anti-IDH2 mAb D328-3 Anti-IDH2-R172K (Human) mAb D332-3 Anti-Mutated IDH1/2 (Human) mAb
使用文献	使用文献募集中！本製品を使って論文を発表されましたら是非お知らせください。 Western Blotting Kaneko MK et al. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. Monoclon Antib Immunodiagn Immunother. 32, 224-8 (2013)(PMID:23750482) Kato Y et al. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun. 432, 564-7 (2013)(PMID:23485467) Ogasawara S et al. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations. Monoclon. Antib. Immunodiagn. Immunother., 32, 377-81 (2013)(PMID:24328739) Liu X et al. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med. 2, 803-14 (2013)(PMID:24403254) Immunocytochemistry Kaneko MK et al. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. Monoclon Antib Immunodiagn Immunother. 32, 224-8 (2013)(PMID:23750482) Immunohistochemistry Ikota H et al. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Brain Tumor Pathol. (2015) In press. (PMID:26006098)
製品カテゴリー	分野がん神経科学

※在庫につきましては2025年01月24日 17時00分時点における在庫数を表示してあります。
※価格の赤色表示につきましては、キャンペーン価格の表示となっております。
※このサイトからは直接注文はできません。ご注意ください。
※使用法の表記について：
WB: Western Blotting, IH: Immunohistochemistry, IC: Immunocytochemistry, IP: Immunoprecipitation,
FCM: Flow Cytometry NT: Neutralization, IF: Immunofluorescence, RIP: RNP Immunoprecipitation,
ChIP: Chromatin Immunoprecipitation, CoIP: Co-Immunoprecipitation
DB: Dot Blotting, NB: Northern Blotting, RNA FISH: RNA Fluorescence in situ hybridization
※使用法・交差性の表記について：
*: 論文で報告されております（MBLでは未確認）。詳しくはデータシートをご覧ください。
**: 導入元からの情報です（MBLでは評価中もしくは未確認）。
※保存温度の表記について： RT: 室温
※本サイトの掲載製品は、品質改良のため予告なく仕様などの変更、または販売中止となる場合がございます。あらかじめご了承ください。